These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 39356250)
1. Comment on the "Analysis of the implementation effect and evaluation of the vaccine protection effect of the live attenuated varicella vaccine program for school-age children in Bao'an district of Shenzhen, China". Cordero DA Hum Vaccin Immunother; 2024 Dec; 20(1):2408879. PubMed ID: 39356250 [No Abstract] [Full Text] [Related]
2. Analysis of the implementation effect and evaluation of the vaccine protection effect of the live attenuated varicella vaccine program for school-age children in Bao'an district of Shenzhen,China. Wang Z; Chen L; Lu F; Peng J; Huang F; Xie X; Kong D Hum Vaccin Immunother; 2024 Dec; 20(1):2364485. PubMed ID: 39053454 [TBL] [Abstract][Full Text] [Related]
3. [Study on epidemiological effect of the freeze-dried attenuated live varicella vaccine]. Ma FB; Luo LY; Zhang LH Zhongguo Yi Miao He Mian Yi; 2009 Jun; 15(3):193-5. PubMed ID: 20084878 [TBL] [Abstract][Full Text] [Related]
4. The impact of the implementation of the two-dose varicella vaccine immunization strategy in Quzhou: A retrospective birth cohort study. Wen T; Fang Q; Fu C; Zheng C; Pan J; Zheng B; Xu W; Yin Z Hum Vaccin Immunother; 2024 Dec; 20(1):2408847. PubMed ID: 39344170 [TBL] [Abstract][Full Text] [Related]
5. Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012. García Cenoz M; Castilla J; Chamorro J; Martínez-Baz I; Martínez-Artola V; Irisarri F; Arriazu M; Ezpeleta C; Barricarte A Euro Surveill; 2013 Aug; 18(32):20552. PubMed ID: 23968827 [No Abstract] [Full Text] [Related]
6. [Systematic reviews and evidence quality assessment on effectiveness of 1 dose varicella attenuated live vaccine for healthy children aged 1-12 years in China]. Zhang ZJZ; Suo LD; Zhao D; Pan JB; Lu L Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Jul; 41(7):1138-1144. PubMed ID: 32741184 [No Abstract] [Full Text] [Related]
7. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Sheffer R; Segal D; Rahamani S; Dalal I; Linhart Y; Stein M; Shohat T; Somekh E Pediatr Infect Dis J; 2005 May; 24(5):434-7. PubMed ID: 15876943 [TBL] [Abstract][Full Text] [Related]
8. Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. Lopez AS; Kolasa MS; Seward JF J Infect Dis; 2008 Mar; 197 Suppl 2():S76-81. PubMed ID: 18419414 [TBL] [Abstract][Full Text] [Related]
9. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M; Güris D; Chaves SS; Schmid S; Seward JF; MMWR Recomm Rep; 2007 Jun; 56(RR-4):1-40. PubMed ID: 17585291 [TBL] [Abstract][Full Text] [Related]
10. The current status of live attenuated varicella vaccine. Gershon AA Arch Virol Suppl; 2001; (17):1-6. PubMed ID: 11339539 [TBL] [Abstract][Full Text] [Related]
11. Impact of a two-dose varicella immunization program on the incidence of varicella: a multi-year observational study in Shanghai, China. Li Z; Yao Y; Lu X; Liu J; Huang Z; Sun X; Lu Y Expert Rev Vaccines; 2021 Sep; 20(9):1177-1183. PubMed ID: 34343035 [TBL] [Abstract][Full Text] [Related]
12. Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program. Ozaki T Vaccine; 2013 Dec; 31(51):6155-60. PubMed ID: 24183712 [TBL] [Abstract][Full Text] [Related]
13. The effectiveness of varicella vaccine in China. Fu C; Wang M; Liang J; Xu J; Wang C; Bialek S Pediatr Infect Dis J; 2010 Aug; 29(8):690-3. PubMed ID: 20216242 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age. Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial. Pan HX; Qiu LX; Liang Q; Chen Z; Zhang ML; Liu S; Zhong GH; Zhu KX; Liao MJ; Hu JL; Li JX; Xu JB; Fan Y; Huang Y; Su YY; Huang SJ; Wang W; Han JL; Jia JZ; Zhu H; Cheng T; Ye XZ; Li CG; Wu T; Zhu FC; Zhang J; Xia NS Lancet Infect Dis; 2024 Aug; 24(8):922-934. PubMed ID: 38614117 [TBL] [Abstract][Full Text] [Related]
16. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Ampofo K; Saiman L; LaRussa P; Steinberg S; Annunziato P; Gershon A Clin Infect Dis; 2002 Mar; 34(6):774-9. PubMed ID: 11830801 [TBL] [Abstract][Full Text] [Related]
17. Live viral vaccines in the control of highly infectious diseases: measles and varicella. Frenkel LD Pediatr Ann; 2004 Sep; 33(9):584-9. PubMed ID: 15462573 [TBL] [Abstract][Full Text] [Related]
18. Two-dose vaccination program shows positive impact on varicella incidence. Riedmann EM Hum Vaccin Immunother; 2013 Dec; 9(12):2500. PubMed ID: 24716205 [No Abstract] [Full Text] [Related]